Literature DB >> 26503800

Survival probabilities with time-dependent treatment indicator: quantities and non-parametric estimators.

Davide Paolo Bernasconi1, Paola Rebora1, Simona Iacobelli2,3, Maria Grazia Valsecchi1, Laura Antolini1.   

Abstract

The 'landmark' and 'Simon and Makuch' non-parametric estimators of the survival function are commonly used to contrast the survival experience of time-dependent treatment groups in applications such as stem cell transplant versus chemotherapy in leukemia. However, the theoretical survival functions corresponding to the second approach were not clearly defined in the literature, and the use of the 'Simon and Makuch' estimator was criticized in the biostatistical community. Here, we review the 'landmark' approach, showing that it focuses on the average survival of patients conditional on being failure free and on the treatment status assessed at the landmark time. We argue that the 'Simon and Makuch' approach represents counterfactual survival probabilities where treatment status is forced to be fixed: the patient is thought as under chemotherapy without possibility to switch treatment or as under transplant since the beginning of the follow-up. We argue that the 'Simon and Makuch' estimator leads to valid estimates only under the Markov assumption, which is however less likely to occur in practical applications. This motivates the development of a novel approach based on time rescaling, which leads to suitable estimates of the counterfactual probabilities in a semi-Markov process. The method is also extended to deal with a fixed landmark time of interest.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Kaplan-Meier; counterfactual survival; immortal time bias; landmark; potential quantities; time-dependent treatment

Mesh:

Year:  2015        PMID: 26503800     DOI: 10.1002/sim.6765

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

Review 1.  Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.

Authors:  Yimei Li; Wei-Ting Hwang; Shannon L Maude; David T Teachey; Noelle V Frey; Regina M Myers; Allison Barz Leahy; Hongyan Liu; David L Porter; Stephan A Grupp; Pamela A Shaw
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

2.  Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.

Authors:  Konstanze Döhner; Christian Thiede; Nikolaus Jahn; Ekaterina Panina; Agnes Gambietz; Richard A Larson; Thomas W Prior; Guido Marcucci; Dan Jones; Jürgen Krauter; Michael Heuser; Maria Teresa Voso; Tiziana Ottone; Josep F Nomdedeu; Sumithra J Mandrekar; Rebecca B Klisovic; Andrew H Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo de Witte; Joop H Jansen; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Richard F Schlenk; Arnold Ganser; Hubert Serve; Gerhard Ehninger; Sergio Amadori; Insa Gathmann; Axel Benner; Celine Pallaud; Richard M Stone; Hartmut Döhner; Clara D Bloomfield
Journal:  Blood       Date:  2020-01-30       Impact factor: 22.113

3.  Understanding Landmarking and Its Relation with Time-Dependent Cox Regression.

Authors:  Hein Putter; Hans C van Houwelingen
Journal:  Stat Biosci       Date:  2016-07-11

4.  The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia.

Authors:  Dennis D H Kim; Igor Novitzky Basso; Taehyung Simon Kim; Seong Yoon Yi; Kyoung Ha Kim; Tracy Murphy; Steven Chan; Mark Minden; Ivan Pasic; Wilson Lam; Arjun Law; Fotios V Michelis; Armin Gerbitz; Auro Viswabandya; Jeffrey Lipton; Rajat Kumar; Stanley W K Ng; Tracy Stockley; Tong Zhang; Ian King; Jonas Mattsson; Jean C Y Wang
Journal:  EJHaem       Date:  2022-05-23

5.  A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan.

Authors:  Paolo Chiodini; Laura Arenare; Maria Carmela Piccirillo; Francesco Perrone; Ciro Gallo
Journal:  Contemp Clin Trials Commun       Date:  2020-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.